In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zur Rose Steams Ahead With Acquisition-Led Expansion Amid Investor Concerns

Executive Summary

Zur Rose adds French online retail platform Doctipharma as two board members resign over “differences of opinion” with regards to the firm's growth strategy.

You may also be interested in...



OTC Supply Bottlenecks Ahead, Warns Europe's Largest Online Pharmacy

Europe's largest e-commerce pharmacy Zur Rose predicts an OTC supply bottleneck down the line as the region's consumer health industry struggles to meet the demand resulting from Covid-19. 

Zur Rose Launches Amazon-Style Retail Platform In Germany

Swiss online retailer Zur Rose is one step closer to realizing its ambition to become the "Amazon of healthcare" with German launch of DocMorris Marktplatz.

Zur Rose’s Experiment In Automated Pharmacy Shut Down For A Second Time

Swiss supply chain disruptor Zur Rose's DocMorris-branded automated pharmacy continues to fall foul of the German legal system.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel